CoChat

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Open access
Park, S., Lee, M.-H., Seong, M., Kim, S.T., Kang, J.-H., Cho, B.C., Lee, K.H., Cho, E.K., Sun, J.-M., Lee, S.-H., Ahn, J.S., Park, K., Ahn, M.-J. · 2020 · Annals of Oncology
Cited by 186

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80mg), a third generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of 160mg osimertinib in BM or LM is unclear. PATIENTS AND METHODS This prospective single-arm two cohort study evaluated the efficacy of 160 mg osimertinib in T790M-positive BM or LM NSCLC patients who progressed on prior EGFR TKI (NCT03257124) treatment. The primary endpoints were overall response rate (ORR) (H1=30%) for the BM cohort and overall survival (OS) (H1=5 months) for the LM cohort. RESULTS The median follow-up duration was 10.1 months and 9.6 months for the BM and LM cohorts, respectively. In the BM cohort, intracranial ORR and disease control rate (DCR) were 55.0% and 77.5%, respectively. The median progression-free survival (PFS) was 7.6 months (95% confidential interval [CI] 5.0-16.6); the median OS was 16.9 months (95% CI 7.9-not reached [NR]). In the LM cohort, intracranial DCR was 92.5% and complete response (CR) rate was 12.5%. The median OS was 13.3 months (95%CI 9.1-NR); the median PFS was 8.0 months (95%CI 7.2-NR). Subgroup analyses based on previous exposure to T790M-targeting agents, including 80 mg osimertinib or other third generation EGFR TKIs, showed no difference in PFS in both the BM (n=18, P=0.39) and LM (n=17, P=0.85) cohorts. Previous radiotherapy favored PFS in the BM cohort (hazard ratio 0.42, P=0.04). The most common adverse events were decreased appetite, diarrhea, and skin rash; however, most were grade 1-2. CONCLUSION Thus, 160 mg osimertinib demonstrated promising ORR and survival benefit with a tolerable safety profile in EGFR T790M-positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.06.017

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 186

Metadata

Authors
Park, S., Lee, M.-H., Seong, M., Kim, S. T., Kang, J.-H., Cho, B. C., Lee, K. H., Cho, E. K., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-10
Volume
31
Issue
10
Pages
1397-1404
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3039427377
Cited by
186
References
8
FWCI
13.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. https://app.cochat.ai/papers/10.1016/j.annonc.2020.06.017
The paper
Park, S., Lee, M.-H., Seong, M., Kim, S. T., Kang, J.-H., Cho, B. C., Lee, K. H., Cho, E. K., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J. (2020). A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.06.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.